Travere Therapeutics (TVTX) Common Equity (2011 - 2026)

Travere Therapeutics has reported Common Equity for 16 years, with the latest figure at $98.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity rose 200.79% year-over-year to $98.7 million; the trailing twelve-month figure through Mar 2026 stood at $98.7 million (up 200.79% YoY), and the FY2025 full-year result was $114.8 million, up 94.37% from the prior year.
• Common Equity for Q1 2026 stood at $98.7 million, down from $114.8 million in the prior quarter.
• The five-year high for Common Equity was $279.8 million in Q3 2023, with the low at -$30.5 million in Q3 2024.
• Historically, Common Equity has averaged $103.8 million across 5 years, with a median of $98.7 million in 2026.
• Annual changes were most pronounced in 2023 — Common Equity jumped 368.62% — and 2024, when it sank 110.89%.
• Travere Therapeutics' Common Equity stood at $42.9 million in 2022, then surged by 368.62% to $200.8 million in 2023, then slumped by 70.58% to $59.1 million in 2024, then surged by 94.37% to $114.8 million in 2025, then declined by 14.02% to $98.7 million in 2026.
• The last three Common Equity figures came in at $98.7 million (Q1 2026), $114.8 million (Q4 2025), and $73.6 million (Q3 2025), per Business Quant data.